Description
Hims & Hers Pushes Diagnostics—But GLP-1 Fallout Looms
Hims & Hers used the Super Bowl stage to push its latest offering: a $689 early cancer detection test. It’s a bold move that signals the company’s push into higher-stakes medicine—at a time when it’s already under federal investigation for its compounded weight-loss treatments. Investors see aggressive marketing and topline growth. But behind the splashy rollout is a mounting set of questions about regulatory exposure, scientific readiness, and the risks of consumer misinterpretation. The stock is down, and the disconnect is widening.
